[ad_1]
The Parker Institute for Cancer Immunotherapy, JDRF and Leona M. and Harry B. Helmsley Charitable Trust announced today a collaborative research initiative to better understand this phenomenon and identify the causes of T1D. The three non-profit organizations jointly fund $ 10 million autoimmunity over a period of three years.
"The clinical success of immune checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab has changed the face of cancer treatment, extending the lives of patients who previously had only few These patients develop insulin-dependent diabetes, and no one really understands how or why, "said Parker Institute President and CEO Jeffrey Bluestone, Ph.D., also AW and Mary Margaret Clausen Distinguished Professor of Metabolism and endocrinology University of California at San Francisco (UCSF).
"By putting together this research initiative, we hope to be able to answer key questions that will help us to predict and prevent autoimmunity as a result of an immunotherapy treatment at the same time." future, "said Bluestone. "This is becoming increasingly important as more and more patients are treated with checkpoint inhibitors and other immunotherapies."
It is hoped that this research collaboration on autoimmunity could also shed light on the causes of T1D in the general population.
About 1.25 million people in United States suffer from T1D, an autoimmune disease that develops when pancreatic beta cells producing insulin are mistakenly destroyed by the body's immune system. As a result, the pancreas stops producing insulin, the hormone that controls the blood sugar level.
"We know little about the causes of type 1 diabetes in healthy children and adults," he said. Ben Williams, Ph.D., Helmsley Charitable Trust, Program Manager, DT1. "We believe that this research could reveal profound discoveries regarding all forms of type 1 diabetes, which could lead to new biomarkers for detection and treatment." This partnership is consistent with Helmsley's desire to research and fund research. promising high-risk, mbadive impact. "
This initiative is a collaboration between leading organizations in the field of cancer immunotherapy research and diabetes, brought together for the first time to explore the intersection of these two types of chronic diseases.
"This collaboration brings together leading experts in the immunology of diabetes and cancer to achieve a feat never before achieved: permanently disable an autoimmune response in humans," he said. Aaron J. Kowalski, Ph.D., President and CEO of JDRF. "By investing in this research, we will be able to better understand, in real time, how Type 1 diabetes develops and potentially can deactivate the immune system, so that progression of the disease never occurs."
Researchers participating in the initiative include Kevan Herold, M.D., professor of immunobiology and medicine at Yale School of Medicine in Connecticut; Mark Anderson, M.D., Ph.D., professor at the UCSF Diabetes Center at San Francisco; Jane Buckner, M.D., president and director of translational research at Virginia Mason's Benaroya Research Institute in Seattle; and medical oncologist Osama Rahma, MD, of the Dana-Farber Institute Against Cancer Boston.
The work also articulates with other research projects on autoimmunity at the Parker Institute and JDRF immunology research to stop autoimmune attacks. that target insulin-producing beta cells.
About the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) is radically changing cancer research methods. Founded in 2016 through a $ 250 million gift of a Silicon Valley entrepreneur and philanthropist Sean Parker, the San FranciscoNonprofit is an unprecedented collaboration between the country's leading immunotherapy researchers and cancer centers, including the Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California at Los Angeles, the University of California at San Francisco, the University of Pennsylvania and the University of Texas MD Anderson Cancer Center. The institute also supports the best researchers from other institutions, including City of Hope, the Dana-Farber Cancer Institute and the Fred Hutchinson Cancer Research Center. By forging alliances with academic, industrial and non-profit partners, PICI relies heavily on bold research to fulfill its mission: to accelerate the development of advanced immune therapies that turn all cancers into treatable diseases. More information on www.parkerici.org.
follow us on Twitter | Facebook | LinkedIn | Instagram
About JDRF
JDRF is the international leader in non-profit organizations fighting type 1 diabetes, while helping people with T1D live healthy lives today. Supported by hundreds of thousands of donors, JDRF raises, invests and funds more funds for T1D research than any other organization in the world. As a result, JDRF has played a key role in the major advances in T1D – research on drugs, devices and cells – that have improved lives and brought us closer to our ultimate goal: to heal. JDRF is mission-driven and serves as an aggressive advocate and educational supporter of the T1D community. JDRF has staff and volunteers in United States, has five international affiliates, funds research in more than 20 countries and supports aid insulin efforts in the United States and around the world. Visit jdrf.org to learn more.
About the Helmsley Charitable Trust
The Leona M. and Harry B. Helmsley Charitable Trust aspire to improve lives by supporting outstanding efforts in the United States and around the world in health and local initiative selection. Since the beginning of its active grants in 2008, Helmsley has committed more than $ 2 billion for a wide range of charitable purposes. For more information, please visit helmsleytrust.org.
SOURCE Institute for Research on Immunotherapy Against Cancer, JDRF and Leona M. and Harry B. Helmsley Charitable Trust
Related Links
http://www.parkerici.org
[ad_2]
Source link
